Sign Out
TRAJENTA DUO is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin.
TRAJENTA DUO is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
TRAJENTA DUO is indicated in combination with empagliflozin (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an SGLT2 inhibitor.
TRAJENTA DUO is indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.
Note: Limitation of use: TRAJENTA DUO must not be used in patients with type 1 diabetes or ketoacidosis due to no clinical effects.
Clinical experience of the use of TRAJENTA DUO in patients with pancreatitis history is limited. There is no information if patients' risk from pancreatitis will be increased by the drug. Therefore, TRAJENTA DUO should be used in these patients only when necessary and pancreatitis monitoring is required (see Precautions).
